SCHEMBL1699587

SCHEMBL1699587

O=C(O)Cc1ccc(F)cc1Cl

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.52
KMT2A Q03164 3/20 0.52
ALDH1A1 P00352 2/20 0.52
KDM4E B2RXH2 1/20 0.52
CYP1A2 P05177 1/20 0.52
CYP3A4 P08684 1/20 0.52
CYP2D6 P10635 1/20 0.52
MAPT P10636 1/20 0.52
CYP2C9 P11712 1/20 0.52
HPGD P15428 1/20 0.52
MAPK1 P28482 1/20 0.52
CYP2C19 P33261 1/20 0.52
TSHR P16473 1/20 0.50
HSD11B1 P28845 1/20 0.48
AKR1C3 P42330 1/20 0.46
AKR1C2 P52895 1/20 0.46
AGBL2 Q5U5Z8 1/20 0.46
POLB P06746 3/20 0.45
DUSP3 P51452 1/20 0.45
PTPN5 P54829 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30911087 1.00 MEN1 (0.52) MEN1KMT2AALDH1A1KDM4ECYP1A2
SCHEMBL837008 0.85 ALDH1A1 (0.46) MEN1KMT2AALDH1A1KDM4ECYP1A2
SCHEMBL151879 0.85 TSHR (0.50) MEN1KMT2AALDH1A1KDM4ECYP1A2
SCHEMBL31306705 0.85 TSHR (0.50) MEN1KMT2AALDH1A1KDM4ECYP1A2
SCHEMBL24173290 0.83 L3MBTL1 (0.48) MEN1KMT2AALDH1A1KDM4ECYP1A2
SCHEMBL29718887 0.83 ALDH1A1 (0.44) MEN1KMT2AALDH1A1KDM4ECYP1A2
SCHEMBL1395757 0.83 ALDH1A1 (0.44) MEN1KMT2AALDH1A1KDM4ECYP1A2
SCHEMBL30941510 0.83 L3MBTL1 (0.48) MEN1KMT2AALDH1A1KDM4ECYP1A2
SCHEMBL2395772 0.82 TSHR (0.54) MEN1KMT2AKDM4EMAPTHPGD
SCHEMBL29673144 0.81 MEN1 (0.50) MEN1KMT2AALDH1A1KDM4ECYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 240 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3114715-B1 P-DOPING CROSS-LINKING OF ORGANIC HOLE TRANSPORTERS SIEMENS AG (DE) 2019-10-30 EP claimed
EP-3114715-A1 P-DOPING CROSS-LINKING OF ORGANIC HOLE TRANSPORTERS Siemens Aktiengesellschaft (DE) 2017-01-11 EP claimed
EP-0710648-B1 Method for producing oxyindoles KI CHEMICAL INDUSTRY CO LTD (JP) 2002-04-03 EP claimed
US-5679799-A Method for producing oxyindoles K-I CHEMICAL INDUSTRY CO., LTD. (JP) 1997-10-21 US claimed
EP-0710648-A1 Method for producing oxyindoles K I CHEMICAL INDUSTRY CO., LTD. (JP) 1996-05-08 EP claimed
US-12599587-B2 Chlorinated tetralin compounds and pharmaceutical compositions SPRINGWORKS THERAPEUTICS, INC. (US) 2026-04-14 US disclosed
US-20260034099-A1 CHLORINATED TETRALIN COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS SPRINGWORKS THERAPEUTICS INC (US) 2026-02-05 US disclosed
EP-4079724-B1 2-(2-CHLOROPHENYL)-N-(5-SULFAMOYLISOQUINOLIN-7-YL)ACETAMIDE DERIVATIVES AND SIMILAR COMPOUNDS AS P2X4 ANTAGONISTS FOR THE TREATMENT OF E.G. URINARY TRACT DISEASES WUHAN LL SCIENCE & TECHNOLOGY DEVELOPMENT CO LTD (CN) 2025-11-12 EP disclosed
US-20250188032-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND USES THEREOF BNH RESEARCH CO., LTD. (KR) 2025-06-12 US disclosed
US-20250185502-A1 ORGANIC OPTOELECTRONIC COMPONENT, ORGANIC FUNCTIONAL LAYER, AND METHOD FOR PRODUCING AN OPTOELECTRONIC COMPONENT OSRAM OLED GMBH (DE) 2025-06-05 US disclosed
US-12302747-B2 Optoelectronic component, organic functional layer, and method for producing an optoelectronic component OSRAM OLED GMBH (DE) 2025-05-13 US disclosed
WO-2025071368-A1 POLYMORPHS OF NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS, AND USES THEREOF 주식회사 비엔에이치리서치 2025-04-03 WO disclosed
WO-2000059497-A1 PYRROLIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY MERCK & CO., INC. (US) 2000-10-12 WO disclosed
EP-0983507-A1 TRICYCLIC TETRAHYDROQUINOLINE DERIVATIVES AND TRICYCLIC TETRAHYDROQUINOLINE COMBINATORIAL LIBRARIES Trega Biosciences, Inc. (US) 2000-03-08 EP disclosed
EP-0977989-A1 4-SUBSTITUTED-QUINOLINE DERIVATIVES AND 4-SUBSTITUTE-QUINOLINE COMBINATORIAL LIBRARIES TREGA BIOSCIENCES, INC. (US) 2000-02-09 EP disclosed
US-5925527-A SCREENING NEW PHARMACEUTICALS TREGA BIOSCIENCES, INC. (US) 1999-07-20 US disclosed
WO-1998034115-A1 4-SUBSTITUTED-QUINOLINE DERIVATIVES AND 4-SUBSTITUTE-QUINOLINE COMBINATORIAL LIBRARIES TREGA BIOSCIENCES, INC. (US) 1998-08-06 WO disclosed
WO-1998034111-A1 TRICYCLIC TETRAHYDROQUINOLINE DERIVATIVES AND TRICYCLIC TETRAHYDROQUINOLINE COMBINATORIAL LIBRARIES TREGA BIOSCIENCES, INC. (US) 1998-08-06 WO disclosed
US-5679799-A Method for producing oxyindoles K-I CHEMICAL INDUSTRY CO., LTD. (JP) 1997-10-21 US disclosed
EP-0710648-A1 Method for producing oxyindoles K I CHEMICAL INDUSTRY CO., LTD. (JP) 1996-05-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260034099-A1 CHLORINATED TETRALIN COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS BACE1, BACE2, DSG1 MEN1 295/4885KMT2A 329/4885ALDH1A1 3125/4885
US-12599587-B2 Chlorinated tetralin compounds and pharmaceutical compositions CLIC1, CLCN2, CSNK1D MEN1 616/4885KMT2A 952/4885ALDH1A1 1962/4885
US-20250188032-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND USES THEREOF NLN, GRIN1, GRIN2A MEN1 3053/4885KMT2A 687/4885ALDH1A1 1563/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.